Zacks Research Has Optimistic Outlook of IOVA Q2 Earnings

Key Points

• Zacks Research raised its Q2 2026 EPS estimate for Iovance Biotherapeutics to -$0.18 from -$0.19, signaling slightly improved near-term expectations for the biotech company.
• Despite the upgrade, analysts still expect losses for Iovance over the next several years, with full-year EPS forecasts remaining negative through at least FY2027.
• Analyst views remain mixed overall, with MarketBeat showing a consensus rating of Hold and an average price target of $8.43, while the stock recently traded around $4.30.

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) - Stock analysts at Zacks Research boosted their Q2 2026 EPS estimates for shares of Iovance Biotherapeutics in a research report issued on Wednesday, May 27th. Zacks Research analyst Team now expects that the biotechnology company will post earnings of ($0.18) per share for the quarter, up from their previous estimate of ($0.19). The consensus estimate for Iovance Biotherapeutics' current full-year earnings is ($0.63) per share. Zacks Research also issued estimates for Iovance Biotherapeutics' Q3 2026 earnings at ($0.17) EPS, Q4 2026 earnings at ($0.17) EPS, FY2026 earnings at ($0.71) EPS, Q1 2027 earnings at ($0.13) EPS, Q2 2027 earnings at ($0.11) EPS, Q3 2027 earnings at ($0.11) EPS, Q4 2027 earnings at ($0.11) EPS, FY2027 earnings at ($0.46) EPS, Q1 2028 earnings at ($0.08) EPS and FY2028 earnings at ($0.21) EPS.

Several other brokerages also recently issued reports on IOVA. Weiss Ratings reiterated a "sell (d-)" rating on shares of Iovance Biotherapeutics in a research note on Monday, April 6th. Chardan Capital lowered their target price on shares of Iovance Biotherapeutics from $16.00 to $14.00 and set a "buy" rating on the stock in a report on Thursday, May 7th. The Goldman Sachs Group reissued a "sell" rating and issued a $2.00 price objective on shares of Iovance Biotherapeutics in a research note on Thursday, February 5th. Truist Financial upgraded Iovance Biotherapeutics to a "hold" rating in a research report on Wednesday, March 25th. Finally, UBS Group boosted their target price on shares of Iovance Biotherapeutics from $2.00 to $4.00 and gave the stock a "neutral" rating in a research note on Thursday, March 5th. Five research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Hold" and an average price target of $8.43.

Iovance Biotherapeutics Price Performance

Shares of NASDAQ:IOVA opened at $4.30 on Friday. The stock has a market capitalization of $1.92 billion, a PE ratio of -4.53 and a beta of 0.69. Iovance Biotherapeutics has a one year low of $1.66 and a one year high of $5.63. The company's 50-day moving average price is $3.65 and its two-hundred day moving average price is $3.11.

Iovance Biotherapeutics (NASDAQ:IOVA - Get Free Report) last released its quarterly earnings data on Thursday, May 7th. The biotechnology company reported ($0.19) earnings per share for the quarter, meeting the consensus estimate of ($0.19). The business had revenue of $71.43 million for the quarter, compared to analysts' expectations of $77.84 million. Iovance Biotherapeutics had a negative return on equity of 50.17% and a negative net margin of 123.92%.Iovance Biotherapeutics's revenue for the quarter was up 44.9% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.36) EPS.

Institutional Investors Weigh In On Iovance Biotherapeutics

Several large investors have recently modified their holdings of IOVA. KBC Group NV purchased a new position in shares of Iovance Biotherapeutics during the 1st quarter valued at $34,000. Arcataur Capital Management LLC bought a new stake in Iovance Biotherapeutics in the fourth quarter worth $29,000. Granite Investment Partners LLC bought a new position in shares of Iovance Biotherapeutics during the fourth quarter valued at about $29,000. Motley Fool Asset Management LLC purchased a new position in Iovance Biotherapeutics during the 4th quarter valued at about $29,000. Finally, Sanctuary Advisors LLC purchased a new stake in shares of Iovance Biotherapeutics in the 1st quarter worth about $38,000. Hedge funds and other institutional investors own 77.03% of the company's stock.

Key Stories Impacting Iovance Biotherapeutics

Here are the key news stories impacting Iovance Biotherapeutics this week:

• Positive Sentiment: Zacks Research raised its Q2 2026 EPS estimate to -$0.18 from -$0.19, suggesting slightly better near-term profitability expectations for Iovance Biotherapeutics. Iovance Biotherapeutics analyst estimate update
• Positive Sentiment: The firm also lifted its Q1 2027 EPS forecast to -$0.13 from -$0.16 and Q1 2028 EPS to -$0.08 from -$0.09, reinforcing a somewhat better outlook for future earnings. Iovance Biotherapeutics analyst estimate update
• Positive Sentiment: A Zacks comparison piece said Iovance’s commercial momentum and expanding Amtagvi pipeline make it appear better positioned than Agenus, which may support investor confidence in the company’s growth story. Zacks comparison article
• Neutral Sentiment: Other analyst revisions were mixed, with some longer-dated estimates raised and others lowered, including Q3 2027 and FY2026/FY2028 forecasts; this points to an uncertain but actively watched earnings path. Iovance Biotherapeutics analyst estimate update
• Negative Sentiment: Even after the revisions, analysts still expect Iovance to remain unprofitable over the next several years, with FY2026 EPS at -$0.71 and FY2027 at -$0.46, which can temper enthusiasm. Iovance Biotherapeutics analyst estimate update

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc is a clinical‐stage biotechnology company specializing in the development and commercialization of tumor‐infiltrating lymphocyte (TIL) immunotherapies for the treatment of solid tumors. The company's lead product candidate, lifileucel (formerly LN‐144), is an autologous TIL therapy in late‐stage clinical development for patients with advanced melanoma. Iovance's pipeline also includes next‐generation TIL programs such as LN‐145 for cervical and other human papillomavirus (HPV)‐related cancers, as well as exploratory studies in head and neck, non‐small cell lung, gastric and other solid tumor indications.

Iovance's TIL platform harnesses a patient's own immune system by isolating, expanding and reinfusing tumor‐reactive lymphocytes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.